MedTrace Logo

Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study

NCT03478020 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-06-13

No results posted yet for this study

Summary

This is an open-label, fixed sequence, 4 cycle, drug-drug interaction (DDI) study of AQX-1125 in healthy female subjects on combination oral contraceptives (COC).

Conditions

  • Healthy Volunteer

Interventions

DRUG

AQX-1125

Investigational Drug

DRUG

Combined Oral Contraceptive

COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)

Sponsors & Collaborators

  • Aquinox Pharmaceuticals (Canada) Inc.

    lead INDUSTRY

Principal Investigators

  • Jeroen van de Wetering, MD · PRA Health Sciences

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-22
Primary Completion
2018-03-29
Completion
2018-04-05

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03478020 on ClinicalTrials.gov